AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
glutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1311 | 56-85-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 40 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,STK33,TEK,TGFBR1 | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 10, 2004 | FDA | EMMAUS MEDCL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 178.75 | 22.17 | 37 | 1334 | 7260 | 90619816 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 264.06 | 27.53 | 50 | 792 | 4840 | 42615653 |
| Tendon calcification | 51.98 | 27.53 | 7 | 835 | 71 | 42620422 |
| Acute chest syndrome | 45.60 | 27.53 | 9 | 833 | 1056 | 42619437 |
| Blood parathyroid hormone increased | 29.57 | 27.53 | 7 | 835 | 1920 | 42618573 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisis | 314.36 | 21.44 | 63 | 1801 | 9482 | 110577953 |
| Tendon calcification | 46.49 | 21.44 | 7 | 1857 | 193 | 110587242 |
| Acute chest syndrome | 40.89 | 21.44 | 9 | 1855 | 2094 | 110585341 |
| Blood parathyroid hormone increased | 25.16 | 21.44 | 7 | 1857 | 4241 | 110583194 |
| Tendon rupture | 23.98 | 21.44 | 9 | 1855 | 14069 | 110573366 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AA03 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives |
| FDA CS | M0000922 | Amino Acids |
| FDA EPC | N0000175780 | Amino Acid |
| CHEBI has role | CHEBI:27027 | micronutrient |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:61908 | EC 1.14.13.39 (nitric oxide synthase) inhibitor |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:78675 | fundamental metabolite |
Related Drugs by ATC class:
A16AA Amino acids and derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Short bowel syndrome | indication | 26629001 | DOID:10605 |
| Hb SS disease | symptomatic treatment | 127040003 | DOID:10923 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.17 | acidic |
| pKa2 | 12.12 | acidic |
| pKa3 | 9.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amino acid transporter | Transporter | IC50 | 4.57 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4027901 | VUID |
| N0000177918 | NUI |
| 4025874 | VANDF |
| 4027901 | VANDF |
| C0017797 | UMLSCUI |
| CHEBI:18050 | CHEBI |
| GLN | PDB_CHEM_ID |
| CHEMBL930 | ChEMBL_ID |
| DB00130 | DRUGBANK_ID |
| D005973 | MESH_DESCRIPTOR_UI |
| 5961 | PUBCHEM_CID |
| 1413 | INN_ID |
| 0RH81L854J | UNII |
| 4885 | RXNORM |
| 12067 | MMSL |
| 158599 | MMSL |
| 158601 | MMSL |
| 42020 | MMSL |
| d07315 | MMSL |
| 000928 | NDDF |
| 25761002 | SNOMEDCT_US |
| 412421007 | SNOMEDCT_US |
| 723 | IUPHAR_LIGAND_ID |
| 0RH81L854J | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| L-glutamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-483 | POWDER, FOR SOLUTION | 5 g | ORAL | ANDA | 24 sections |
| Endari | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42457-420 | POWDER, FOR SOLUTION | 5 g | ORAL | NDA | 26 sections |
| L-Glutamine | Human Prescription Drug Label | 1 | 70954-417 | POWDER, FOR SOLUTION | 5 g | ORAL | ANDA | 23 sections |
| L-Glutamine | Human Prescription Drug Label | 1 | 70954-417 | POWDER, FOR SOLUTION | 5 g | ORAL | ANDA | 23 sections |
| L-glutamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 84897-057 | POWDER, FOR SOLUTION | 5 g | ORAL | ANDA | 24 sections |